| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834010 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
| US5601839 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
| US7081250 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081251 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US6743441 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081252 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081249 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
Oxytrol For Women is owned by Abbvie.
Oxytrol For Women contains Oxybutynin.
Oxytrol For Women has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Oxytrol For Women are:
- US5834010
- US5601839
- US7081250
- US7081251
- US6743441
- US7081252
- US7081249
- US7179483
Oxytrol For Women was authorised for market use on 25 January, 2013.
Oxytrol For Women is available in film, extended release;transdermal dosage forms.
Oxytrol For Women can be used as treatment of patients with an overactive bladder.
The generics of Oxytrol For Women are possible to be released after 26 April, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 25, 2016 |
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Treatment of patients with an overactive bladder
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN family patents
